Compass Therapeutics said its cancer treatment improved progression-free survival in a recent trial, but didn't meet its secondary endpoint in overall survival. Shares fell 23% to $3.85 in premarket ...
Compass Therapeutics shed half its stock price this morning as investors digested its bispecific antibody’s failure to hit an ...
While tovecimig met the main goal of progression-free survival in a Phase 2/3 trial, it did not improve overall survival.
Compass Therapeutics Inc. CMPX shares are tumbling on Monday as the company announced results from its COMPANION-002 study, ...
Investing.com -- Compass Therapeutics (NASDAQ:CMPX) shares tumbled 80% Monday following mixed results from its Phase II/III COMPANION-002 trial evaluating tovecimig combined with paclitaxel in ...
Compass Group’s fair value estimate has been trimmed slightly from $38.60 to about $38.50, a move of roughly 0.3% that ...
The FDA is awarding national priority vouchers to Compass Pathways and the Usona Institute as the Trump administration looks ...
Third Avenue Small-Cap Value Fund initiated a position in Compass, Inc. following its merger with Anywhere. Read the full ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results